ArticleCell reports2026
Mechanistic modeling reveals a configurable AP-1 network governing cell-state heterogeneity and adaptive plasticity in melanoma cells.
Article in Cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
4 authors.
Funding
Abstract
AP-1 transcription factors have been implicated in cellular plasticity, differentiation-state heterogeneity, and phenotype switching, enabling adaptation to anti-cancer therapies. Although AP-1 states, defined by the combinatorial expression of AP-1 proteins, are heterogeneous within cell populations, only a subset of possible states is observed. How these states are constrained, why their distributions vary across cell populations, and what drives their phenotypically consequential transitions remain unclear. We develop a mechanistic model of the AP-1 network, capturing dimerization-dependent, co-regulated, and competitive interactions. Calibrated to single-cell protein measurements across diverse melanoma populations and combined with statistical learning, the model reveals parameters explaining population-specific AP-1 state distributions. These parameters correlate with MAPK signaling across cell populations. The model predicts and experiments validate adaptive AP-1 reconfiguration following MAPK inhibition, driving a dedifferentiated, therapy-resistant state that is attenuated through model-guided perturbations. These findings establish AP-1 as a configurable network and provide a framework for modulating AP-1-driven cell-state plasticity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.